1
|
Gianò M, Franco C, Castrezzati S, Rezzani R. Involvement of Oxidative Stress and Nutrition in the Anatomy of Orofacial Pain. Int J Mol Sci 2023; 24:13128. [PMID: 37685933 PMCID: PMC10487620 DOI: 10.3390/ijms241713128] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 08/13/2023] [Accepted: 08/17/2023] [Indexed: 09/10/2023] Open
Abstract
Pain is a very important problem of our existence, and the attempt to understand it is one the oldest challenges in the history of medicine. In this review, we summarize what has been known about pain, its pathophysiology, and neuronal transmission. We focus on orofacial pain and its classification and features, knowing that is sometimes purely subjective and not well defined. We consider the physiology of orofacial pain, evaluating the findings on the main neurotransmitters; in particular, we describe the roles of glutamate as approximately 30-80% of total peripheric neurons associated with the trigeminal ganglia are glutamatergic. Moreover, we describe the important role of oxidative stress and its association with inflammation in the etiogenesis and modulation of pain in orofacial regions. We also explore the warning and protective function of orofacial pain and the possible action of antioxidant molecules, such as melatonin, and the potential influence of nutrition and diet on its pathophysiology. Hopefully, this will provide a solid background for future studies that would allow better treatment of noxious stimuli and for opening new avenues in the management of pain.
Collapse
Affiliation(s)
- Marzia Gianò
- Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy; (M.G.); (C.F.); (S.C.)
| | - Caterina Franco
- Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy; (M.G.); (C.F.); (S.C.)
| | - Stefania Castrezzati
- Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy; (M.G.); (C.F.); (S.C.)
| | - Rita Rezzani
- Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy; (M.G.); (C.F.); (S.C.)
- Interdipartimental University Center of Research “Adaption and Regeneration of Tissues and Organs (ARTO)”, University of Brescia, 25123 Brescia, Italy
- Italian Society for the Study of Orofacial Pain (Società Italiana Studio Dolore Orofacciale—SISDO), 25123 Brescia, Italy
| |
Collapse
|
2
|
Sadighparvar S, Al-Hamed FS, Sharif-Naeini R, Meloto CB. Preclinical orofacial pain assays and measures and chronic primary orofacial pain research: where we are and where we need to go. FRONTIERS IN PAIN RESEARCH 2023; 4:1150749. [PMID: 37293433 PMCID: PMC10244561 DOI: 10.3389/fpain.2023.1150749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 04/11/2023] [Indexed: 06/10/2023] Open
Abstract
Chronic primary orofacial pain (OFP) conditions such as painful temporomandibular disorders (pTMDs; i.e., myofascial pain and arthralgia), idiopathic trigeminal neuralgia (TN), and burning mouth syndrome (BMS) are seemingly idiopathic, but evidence support complex and multifactorial etiology and pathophysiology. Important fragments of this complex array of factors have been identified over the years largely with the help of preclinical studies. However, findings have yet to translate into better pain care for chronic OFP patients. The need to develop preclinical assays that better simulate the etiology, pathophysiology, and clinical symptoms of OFP patients and to assess OFP measures consistent with their clinical symptoms is a challenge that needs to be overcome to support this translation process. In this review, we describe rodent assays and OFP pain measures that can be used in support of chronic primary OFP research, in specific pTMDs, TN, and BMS. We discuss their suitability and limitations considering the current knowledge of the etiology and pathophysiology of these conditions and suggest possible future directions. Our goal is to foster the development of innovative animal models with greater translatability and potential to lead to better care for patients living with chronic primary OFP.
Collapse
Affiliation(s)
- Shirin Sadighparvar
- Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada
- The Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada
| | | | - Reza Sharif-Naeini
- The Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada
- Department of Physiology and Cell Information Systems, McGill University, Montreal, QC, Canada
| | - Carolina Beraldo Meloto
- The Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada
| |
Collapse
|
3
|
Sampaio GMMS, Vieira-Neto AE, Leite GDO, Campos AR. Melatonin promotes orofacial antinociception in adult zebrafish by modulating TRP channels. Physiol Behav 2023:114238. [PMID: 37207745 DOI: 10.1016/j.physbeh.2023.114238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 04/25/2023] [Accepted: 05/12/2023] [Indexed: 05/21/2023]
Abstract
Melatonin is an endogenous hormone, known as the sleep hormone, which has already demonstrated its antinociceptive effect. This study aimed to evaluate the participation of TRP's channels in the orofacial antinociceptive effect of melatonin (MT) in adult zebrafish. Initially, the open field test was performed to evaluate the effect of MT on the locomotor activity of adult zebrafish. Then, the animals were pre-treated with MT (0.1, 0.3 or 1 mg/mL; gavage) and acute orofacial nociception was induced by the application of capsaicin (TRPV1 agonist), cinnamaldehyde (TRPA1 agonist) or menthol (TRPM8 agonist) applied into the animal's lip. Naive groups were included. MT, per se, did not alter the locomotor activity of the animals. MT reduced the nociceptive behaviour induced by the three agonists; however, the most significant effect was obtained with the lowest concentration tested (0.1 mg/mL) in the capsaicin test. The orofacial antinociceptive effect of melatonin was prevented by capsazepine (TRPV1 antagonist), but not by HC-030031 (TRPA1 antagonist). The molecular docking study indicated interaction between MT and the TRPV1, TRPA1 and TRPM8 channels and, in line with the in vivo results, there was greater affinity between MT and the TRPV1 channel. The results confirm the pharmacological relevance of melatonin as an inhibitor of orofacial nociception and this effect seems to be related to the modulation of TRP's channels.
Collapse
|
4
|
Finamor F, Scarabelot VL, Medeiros LF, Stein DJ, da Silva MD, Callai E, Caumo W, de Souza A, Torres ILS. Involvement of GABAergic, glutamatergic, opioidergic, and brain-derived neurotrophic factor systems in the trigeminal neuropathic pain process. Neurosci Lett 2023; 793:136970. [PMID: 36402255 DOI: 10.1016/j.neulet.2022.136970] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 11/11/2022] [Accepted: 11/14/2022] [Indexed: 11/18/2022]
Abstract
Trigeminal neuropathic pain (TNP) is an intense pain condition characterized by hyperalgesia and allodynia; however, its neural mechanisms are not completely understood. Its management is complex, and studies that investigate its biochemical mechanisms are important for improving clinical approaches. This study aimed to evaluate the involvement of GABAergic, glutamatergic, and opioidergic systems and brain-derived neurotrophic factor (BDNF) levels in the TNP process in rats. TNP is induced by chronic constriction injury of the infraorbital nerve (CCI-ION). Nociceptive responses were evaluated using the facial von Frey test before and after the administration of GABAergic and opioidergic agonists and glutamatergic antagonists. The rats were divided into vehicle-treated control (C), sham-surgery (SS), and CCI-ION groups, and then subdivided into the vehicle (V)-treated SS-V and CCI-ION-V groups, SS-MK801 and CCI-ION-MK801, treated with the N-methyl-d-aspartate receptor selective antagonist MK801; SS-PB and CCI-ION-PB, treated with phenobarbital; SS-BZD and CCI-ION-BZD, treated with diazepam; SS-MOR and CCI-ION-MOR, treated with morphine. BDNF levels were evaluated in the cerebral cortex, brainstem, trigeminal ganglion, infraorbital branch of the trigeminal nerve, and serum. CCI-ION induced facial mechanical hyperalgesia. Phenobarbital and morphine reversed the hyperalgesia induced by CCI-ION, and the CCI-BZD group had an increased nociceptive threshold until 60 min. CCI-ION-GLU increased the nociceptive threshold at 60 min. Cerebral cortex and brainstem BDNF levels increased in the CCI-ION and SS groups. Only the CCI group presented high levels of BDNF in the trigeminal ganglion. Our data suggest the involvement of GABAergic, glutamatergic, and opioidergic systems and peripheral BDNF in the TNP process.
Collapse
Affiliation(s)
- Fabrício Finamor
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil
| | - Vanessa Leal Scarabelot
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil
| | - Liciane Fernandes Medeiros
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil; Universidade La Salle, Canoas, RS, Brazil
| | - Dirson João Stein
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil; School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Morgana Duarte da Silva
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil
| | - Etiane Callai
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil
| | - Wolnei Caumo
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil; School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Andressa de Souza
- School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Iraci L S Torres
- Nucleus of Pain Pharmacology and Neuromodulation. Hospital de Clínicas de Porto Alegre, RS, Brazil; School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
| |
Collapse
|
5
|
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms. Cells 2022; 11:cells11233795. [PMID: 36497053 PMCID: PMC9736455 DOI: 10.3390/cells11233795] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 11/16/2022] [Accepted: 11/24/2022] [Indexed: 11/29/2022] Open
Abstract
Migraine is a complex neurovascular disorder, which causes intense socioeconomic problems worldwide. The pathophysiology of disease is enigmatic; accordingly, therapy is not sufficient. In recent years, migraine research focused on tryptophan, which is metabolized via two main pathways, the serotonin and kynurenine pathways, both of which produce neuroactive molecules that influence pain processing and stress response by disturbing neural and brain hypersensitivity and by interacting with molecules that control vascular and inflammatory actions. Serotonin has a role in trigeminal pain processing, and melatonin, which is another product of this pathway, also has a role in these processes. One of the end products of the kynurenine pathway is kynurenic acid (KYNA), which can decrease the overexpression of migraine-related neuropeptides in experimental conditions. However, the ability of KYNA to cross the blood-brain barrier is minimal, necessitating the development of synthetic analogs with potentially better pharmacokinetic properties to exploit its therapeutic potential. This review summarizes the main translational and clinical findings on tryptophan metabolism and certain neuropeptides, as well as therapeutic options that may be useful in the prevention and treatment of migraine.
Collapse
|
6
|
Dos Santos FM, Pflüger PF, Lazzarotto L, Uczay M, de Aguida WR, da Silva LS, Boaretto FBM, de Sousa JT, Picada JN, da Silva Torres IL, Pereira P. Gamma-Decanolactone Alters the Expression of GluN2B, A 1 Receptors, and COX-2 and Reduces DNA Damage in the PTZ-Induced Seizure Model After Subchronic Treatment in Mice. Neurochem Res 2021; 46:2066-2078. [PMID: 34019198 DOI: 10.1007/s11064-021-03345-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 04/05/2021] [Accepted: 05/12/2021] [Indexed: 11/26/2022]
Abstract
Gamma-decanolactone (GD) has been shown to reduce epileptic behavior in different models, inflammatory decreasing, oxidative stress, and genotoxic parameters. This study assessed the GD effect on the pentylenetetrazole (PTZ) model after acute and subchronic treatment. We evaluated the expression of the inflammatory marker cyclooxygenase-2 (COX-2), GluN2B, a subunit of the NMDA glutamate receptor, adenosine A1 receptor, and GD genotoxicity and mutagenicity. Male and female mice were treated with GD (300 mg/kg) for 12 days. On the tenth day, they were tested in the Hot Plate test. On the thirteenth day, all animals received PTZ (90 mg/kg), and epileptic behavior PTZ-induced was observed for 30 min. Pregabalin (PGB) (30 mg/kg) was used as a positive control. Samples of the hippocampus and blood were collected for Western Blotting analyses and Comet Assay and bone marrow to the Micronucleus test. Only the acute treatment of GD reduced the seizure occurrence and increased the latency to the first stage 3 seizures. Males treated with GD for 12 days demonstrated a significant increase in the expression of the GluN2B receptor and a decrease in the COX-2 expression. Acute and subchronic treatment with GD and PGB reduced the DNA damage produced by PTZ in males and females. There is no increase in the micronucleus frequency in bone marrow after subchronic treatment. This study suggests that GD, after 12 days, could not reduce PTZ-induced seizures, but it has been shown to protect against DNA damage, reduce COX-2 and increase GluN2B expression.
Collapse
Affiliation(s)
- Fernanda Marcelia Dos Santos
- Laboratory of Neuropharmacology and Preclinical Toxicology, Health Basic Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Pricila Fernandes Pflüger
- Laboratory of Neuropharmacology and Preclinical Toxicology, Health Basic Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Leticia Lazzarotto
- Laboratory of Neuropharmacology and Preclinical Toxicology, Health Basic Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Mariana Uczay
- Laboratory of Neuropharmacology and Preclinical Toxicology, Health Basic Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Wesley Roberto de Aguida
- Laboratory of Neuropharmacology and Preclinical Toxicology, Health Basic Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Lisiane Santos da Silva
- Laboratory of Pain Pharmacology and Neuromodulation: Pre-Clinical Research. Postgraduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | | | | | | | - Iraci Lucena da Silva Torres
- Laboratory of Pain Pharmacology and Neuromodulation: Pre-Clinical Research. Postgraduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Patrícia Pereira
- Laboratory of Neuropharmacology and Preclinical Toxicology, Health Basic Sciences Institute, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
- Laboratory of Neuropharmacology and Preclinical Toxicology, Department of Pharmacology, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Sarmento Leite 500/305, Porto Alegre, RS, CEP 90050-170, Brazil.
| |
Collapse
|
7
|
Nicot R, Barry F, Chijcheapaza-Flores H, Garcia-Fernandez MJ, Raoul G, Blanchemain N, Chai F. A Systematic Review of Rat Models With Temporomandibular Osteoarthritis Suitable for the Study of Emerging Prolonged Intra-Articular Drug Delivery Systems. J Oral Maxillofac Surg 2021; 79:1650-1671. [PMID: 33775650 DOI: 10.1016/j.joms.2021.02.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 02/20/2021] [Accepted: 02/22/2021] [Indexed: 11/29/2022]
Abstract
PURPOSE Development of minimally invasive therapies for temporomandibular joint osteoarthritis (TMJOA) has focused on drug intra-articular injections to avoid the systemic adverse effects experienced when these substances are administered orally. Therefore, we performed a systematic review to answer the question "Which method of induction of a TMJOA-related pain model in rats leads to prolonged painful symptoms, allowing the best assessment of a sustained drug delivery system?" MATERIALS AND METHODS Following the PRISMA guidelines, we searched MEDLINE for papers published from 1994 to July 2020 on a TMJ arthritis model using rats. We identified the means of pain induction and of nociception assessment. We assessed protocol bias using an adaptation of the QUADAS-2 tool. Animal selection, the reference standard method of pain assessment, applicability of a statistical assessment, and flow and timing were assessed. RESULTS Of the 59 full papers we reviewed, 41 performed no pain assessment after the first 7 days following induction of the TMJ-related pain model. We eventually identified 18 long-term TMJOA-related pain models. Pain was induced by injection of toxic substances, most commonly Freund's complete adjuvant (50 μg per 50 μl), formalin at various concentrations, or monosodium iodoacetate (0,5 mg per 50 μl), into the TMJ, or by physical methods. Few studies reported data on pain after 21 days of follow-up. Heterogeneity of induction methods, pain assessment methods, and flow and timing biases precluded a meta-analysis. CONCLUSIONS Given that pain is 1 of the main symptoms of TMJOA, experimental study protocols should include long-term pain assessment.
Collapse
Affiliation(s)
- Romain Nicot
- Associate Professor, Univ. Lille, CHU Lille, INSERM, Service de Chirurgie Maxillo-Faciale et Stomatologie, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France.
| | - Florent Barry
- Resident, Univ. Lille, CHU Lille, INSERM, Service de Chirurgie Maxillo-Faciale et Stomatologie, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France
| | - Henry Chijcheapaza-Flores
- Research Assistant, Univ. Lille, INSERM, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France
| | - Maria José Garcia-Fernandez
- Associate Professor, Univ. Lille, INSERM, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France
| | - Gwénaël Raoul
- Professor, Univ. Lille, CHU Lille, INSERM, Service de Chirurgie Maxillo-Faciale et Stomatologie, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France
| | - Nicolas Blanchemain
- Professor, Department Head, Univ. Lille, INSERM, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France
| | - Feng Chai
- Research engineer, Univ. Lille, INSERM, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France
| |
Collapse
|
8
|
Wu ZY, Huang SD, Zou JJ, Wang QX, Naveed M, Bao HN, Wang W, Fukunaga K, Han F. Autism spectrum disorder (ASD): Disturbance of the melatonin system and its implications. Biomed Pharmacother 2020; 130:110496. [DOI: 10.1016/j.biopha.2020.110496] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 06/25/2020] [Accepted: 07/02/2020] [Indexed: 12/15/2022] Open
|
9
|
Xie S, Fan W, He H, Huang F. Role of Melatonin in the Regulation of Pain. J Pain Res 2020; 13:331-343. [PMID: 32104055 PMCID: PMC7012243 DOI: 10.2147/jpr.s228577] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2019] [Accepted: 01/20/2020] [Indexed: 12/15/2022] Open
Abstract
Melatonin is a pleiotropic hormone synthesized and secreted mainly by the pineal gland in vertebrates. Melatonin is an endogenous regulator of circadian and seasonal rhythms. Melatonin is involved in many physiological and pathophysiological processes demonstrating antioxidant, antineoplastic, anti-inflammatory, and immunomodulatory properties. Accumulating evidence has revealed that melatonin plays an important role in pain modulation through multiple mechanisms. In this review, we examine recent evidence for melatonin on pain regulation in various animal models and patients with pain syndromes, and the potential cellular mechanisms.
Collapse
Affiliation(s)
- Shanshan Xie
- Department of Pediatric Dentistry, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, People's Republic of China.,Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, People's Republic of China
| | - Wenguo Fan
- Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, People's Republic of China.,Department of Anesthesiology, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Hongwen He
- Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, People's Republic of China.,Department of Oral Anatomy and Physiology, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Fang Huang
- Department of Pediatric Dentistry, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, People's Republic of China.,Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, People's Republic of China
| |
Collapse
|
10
|
Callai EMM, Scarabelot VL, Fernandes Medeiros L, Oliveira C, Souza A, Macedo IC, Cioato SG, Finamor F, Caumo W, Quevedo ADS, Torres ILS. Transcranial direct current stimulation (tDCS) and trigeminal pain: A preclinical study. Oral Dis 2019; 25:888-897. [DOI: 10.1111/odi.13038] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2018] [Revised: 12/04/2018] [Accepted: 12/21/2018] [Indexed: 12/28/2022]
Affiliation(s)
- Etiane Micheli Meyer Callai
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Graduate Program in Biological Sciences: Physiology ICBS, UFRGS Porto Alegre Brazil
| | - Vanessa Leal Scarabelot
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
| | - Liciane Fernandes Medeiros
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Postgraduate Program in Medical Sciences, School of Medicine Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
| | - Carla Oliveira
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Postgraduate Program in Medical Sciences, School of Medicine Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
| | - Andressa Souza
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Post‐Graduate Program in Health and Human Development, Centro Universitário Unilasalle Canoas Brazil
| | - Isabel Cristina Macedo
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
| | - Stefania Giotti Cioato
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Graduate Program in Biological Sciences: Pharmacology and Therapeutics ICBS, UFRGS Porto Alegre Brazil
| | - Fabrício Finamor
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Graduate Program in Biological Sciences: Pharmacology and Therapeutics ICBS, UFRGS Porto Alegre Brazil
| | - Wolnei Caumo
- Postgraduate Program in Medical Sciences, School of Medicine Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
| | - Alexandre da Silva Quevedo
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Graduate Program in Biological Sciences: Pharmacology and Therapeutics ICBS, UFRGS Porto Alegre Brazil
| | - Iraci L. S. Torres
- Pharmacology of Pain and Neuromodulation Laboratory: Preclinical Researches, Department of Pharmacology, Institute of Basic Health Sciences (ICBS) Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
- Animal Experimentation Unit and Graduate Research Group Hospital de Clínicas de Porto Alegre Porto Alegre Brazil
- Graduate Program in Biological Sciences: Physiology ICBS, UFRGS Porto Alegre Brazil
- Postgraduate Program in Medical Sciences, School of Medicine Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
- Graduate Program in Biological Sciences: Pharmacology and Therapeutics ICBS, UFRGS Porto Alegre Brazil
| |
Collapse
|
11
|
Araújo-Filho HG, Pereira EWM, Campos AR, Quintans-Júnior LJ, Quintans JSS. Chronic orofacial pain animal models - progress and challenges. Expert Opin Drug Discov 2018; 13:949-964. [PMID: 30220225 DOI: 10.1080/17460441.2018.1524458] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Chronic orofacial pain is one of the most common pain conditions experienced by adults. Animal models are often selected as the most useful scientific methodology to explore the pathophysiology of the disorders that cause this disabling pain to facilitate the development of new treatments. The creation of new models or the improvement of existing ones is essential for finding new ways to approach the complex neurobiology of this type of pain. Areas covered: The authors describe and discuss a variety of animal models used in chronic orofacial pain (COFP). Furthermore, they examine in detail the mechanisms of action involved in orofacial neuropathic pain and orofacial inflammatory pain. Expert opinion: The use of animal models has several advantages in chronic orofacial pain drug discovery. Choosing an animal model that most closely represents the human disease helps to increase the chances of finding effective new therapies and is key to the successful translation of preclinical research to clinical practice. Models using genetically modified animals seem promising but have not yet been fully developed for use in chronic orofacial pain research. Although animal models have provided significant advances in the pharmacological treatment of orofacial pain, several barriers still need to be overcome for better treatment options.
Collapse
Affiliation(s)
- Heitor G Araújo-Filho
- a Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology , Federal University of Sergipe , São Cristóvão , Brazil
| | - Erik W M Pereira
- a Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology , Federal University of Sergipe , São Cristóvão , Brazil
| | - Adriana Rolim Campos
- b Experimental Biology Centre (NUBEX) , University of Fortaleza (UNIFOR) , Fortaleza , Brazil
| | - Lucindo J Quintans-Júnior
- a Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology , Federal University of Sergipe , São Cristóvão , Brazil
| | - Jullyana S S Quintans
- a Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology , Federal University of Sergipe , São Cristóvão , Brazil
| |
Collapse
|
12
|
Gagnon K, Godbout R. Melatonin and Comorbidities in Children with Autism Spectrum Disorder. CURRENT DEVELOPMENTAL DISORDERS REPORTS 2018; 5:197-206. [PMID: 30148039 PMCID: PMC6096870 DOI: 10.1007/s40474-018-0147-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
PURPOSE OF REVIEW Melatonin is used to treat sleep difficulties associated with autism spectrum disorder (ASD). There are growing evidence that melatonin could have an effect on other symptoms than sleep, such as anxiety, depression, pain, and gastrointestinal dysfunctions. Interestingly, these symptoms frequently are found as comorbid conditions in individuals with ASD. We aimed to highlight the potential effect of melatonin on these symptoms. RECENT FINDINGS Animal and human studies show that melatonin reduces anxiety. Regarding the effect of melatonin on pain, animal studies are promising, but results remain heterogeneous in humans. Both animal and human studies have found that melatonin can have a positive effect on gastrointestinal dysfunction. SUMMARY Melatonin has the potential to act on a wide variety of symptoms associated with ASD. However, other than sleep difficulties, no studies exist on melatonin as a treatment for ASD comorbid conditions. Such investigations should be on the research agenda because melatonin could improve a multitude of ASD comorbidities and, consequently, improve well-being.
Collapse
Affiliation(s)
- Katia Gagnon
- Sleep Laboratory & Clinic, Hôpital Rivière-des-Prairies, CIUSSS du Nord-de-l’Île-de-Montréal, 7070 Boul. Perras, Montréal, Québec H1E 1A4 Canada
- Department of Psychiatry, Université de Montréal, Montréal, Québec Canada
| | - Roger Godbout
- Sleep Laboratory & Clinic, Hôpital Rivière-des-Prairies, CIUSSS du Nord-de-l’Île-de-Montréal, 7070 Boul. Perras, Montréal, Québec H1E 1A4 Canada
- Department of Psychiatry, Université de Montréal, Montréal, Québec Canada
| |
Collapse
|
13
|
Melatonin Attenuates Pain Hypersensitivity and Decreases Astrocyte-Mediated Spinal Neuroinflammation in a Rat Model of Oxaliplatin-Induced Pain. Inflammation 2018; 40:2052-2061. [PMID: 28812173 DOI: 10.1007/s10753-017-0645-y] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Neuroinflammatory response in spinal dorsal horn has been demonstrated to be a critical factor in oxaliplatin-induced pain. Melatonin has been shown to have anti-inflammatory and anti-allodynia effects in both preclinical and clinical studies. In the present study, we investigated the role of systemic administration of melatonin on oxaliplatin-induced pain. Intraperitoneal (i.p.) injection with oxaliplatin induced significantly mechanical allodynia and thermal hyperalgesia. Melatonin (i.p.) significantly alleviated mechanical allodynia and thermal hyperalgesia in the oxaliplatin but not sham-treated rats. The attenuation of nociceptive response persisted at least to 3 days after melatonin injection, throughout the entire observing window. Immunohistochemistry showed that oxaliplatin induced a significant increase of glial fibrillary acidic protein (GFAP) immunodensities, which could be suppressed by melatonin. Western blotting showed that GFAP protein levels were significantly elevated in the oxaliplatin-vehicle group. Melatonin significantly decreased oxaliplatin-induced upregulation of GFAP expressions. Oxaliplatin injection also enhanced the messenger RNA (mRNA) expressions of cytokines including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) and chemokines including monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1 (MIP-1α) in the spinal dorsal horn, which could be significantly repressed by melatonin. In vitro study showed that mRNA levels of TNF-α, IL-1β, MCP-1, and MIP-1α in primarily astrocytes were significantly increased after lipopolysaccharide (LPS, 1 μg/ml) stimulation. Melatonin (10 and 100 μM) greatly inhibited synthesis of these inflammatory mediators, in a dose-related manner. Conclusively, our data provide a novel implication of anti-nociceptive mechanism of melatonin in chemotherapy-related pain.
Collapse
|
14
|
Spezia Adachi LN, Vercelino R, de Oliveira C, Scarabelot VL, de Souza A, Medeiros LF, Cioato SG, Caumo W, Torres ILS. Isoflurane and the Analgesic Effect of Acupuncture and Electroacupuncture in an Animal Model of Neuropathic Pain. J Acupunct Meridian Stud 2018; 11:97-106. [PMID: 29436370 DOI: 10.1016/j.jams.2018.01.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 01/30/2018] [Accepted: 01/31/2018] [Indexed: 12/17/2022] Open
Abstract
The present study aimed to determine whether isoflurane interferes with the analgesic effects of acupuncture (Ac) and electroacupuncture (EA), using a neuropathic pain (NP) rat model. In total, 140 male Wistar rats were used; isoflurane-induced nociceptive response was evaluated using the von Frey test, serum calcium-binding protein β (S100β) levels and nerve growth factor (NGF) levels in the left sciatic nerve. The NP model was induced by chronic constriction injury of the sciatic nerve at 14 days after surgery. Treatment was initiated after NP induction with or without isoflurane anesthesia (20 min/day/8 days). The von Frey test was performed at baseline, 14 days postoperatively, and immediately, 24 h, and 48 h after the last treatment. Results of the nociceptive test and three-way analysis of variance were analyzed by generalized estimating equations, the Bonferroni test, followed by Student-Newman-Keuls or Fisher's least significant difference tests for comparing biochemical parameters (significance defined as p ≤ 0.05). At baseline, no difference was noted in the nociceptive response threshold among all groups. Fourteen days after surgery, compared with other groups, NP groups showed a decreased pain threshold, confirming establishment of NP. Ac and EA enhanced the mechanical pain threshold immediately after the last session in the NP groups, without anesthesia. Isoflurane administration caused increased nociceptive threshold in all groups, and this effect persisted for 48 h after the last treatment. There was an interaction between the independent variables: pain, treatments, and anesthesia in serum S100β levels and NGF levels in the left sciatic nerve. Isoflurane enhanced the analgesic effects of Ac and EA and altered serum S100β and left sciatic nerve NGF levels in rats with NP.
Collapse
Affiliation(s)
- Lauren N Spezia Adachi
- Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Rafael Vercelino
- Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Centro Universitário FADERGS, Health and Wellness School Laureate International Universities, Porto Alegre, RS, Brazil
| | - Carla de Oliveira
- Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Vanessa L Scarabelot
- Graduate Program in Biological Sciences, Physiology, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Andressa de Souza
- Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Liciane F Medeiros
- Graduate Program in Biological Sciences, Physiology, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Stefania G Cioato
- Graduate Program in Biological Sciences, Pharmacology and Therapeutics, Institute of Basic Health Sciences, Universidade Federal Rio Grande do Sul, Porto Alegre, RS, 90050-170, Brazil; Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Wolnei Caumo
- Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Iraci L S Torres
- Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Graduate Program in Biological Sciences, Physiology, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Graduate Program in Biological Sciences, Pharmacology and Therapeutics, Institute of Basic Health Sciences, Universidade Federal Rio Grande do Sul, Porto Alegre, RS, 90050-170, Brazil; Laboratory of Pain Pharmacology and Neuromodulation: Preclinical Researchs, Department of Pharmacology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil; Animal Experimentation Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
| |
Collapse
|
15
|
Mortazavi SAR, Mortazavi SMJ, Paknahad M. Comments on 'Neuroprotective effects of melatonin and omega-3 on hippocampal cells prenatally exposed to 900 MHz electromagnetic fields'. Int J Radiat Biol 2017; 93:661-662. [PMID: 28332426 DOI: 10.1080/09553002.2017.1310403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- S A R Mortazavi
- a Research Committee , School of Medicine, Shiraz University of Medical Sciences , Shiraz , Iran
| | - Seyed Mohammad Javad Mortazavi
- b Medical Physics, Medical Physics Department , School of Medicine, Shiraz University of Medical Sciences , Shiraz , Iran.,c Ionizing and Non-ionizing Radiation Protection Research Center (INIRPRC) , Shiraz University of Medical Sciences , Shiraz , Iran
| | - Maryam Paknahad
- d Dentomaxillofacial Radiology , School of Dentistry, Shiraz University of Medical Sciences , Shiraz , Iran
| |
Collapse
|